-
August 2, 2024
-
August 2, 2024
-
August 2, 2024
-
September 5, 2024
EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024
-
September 2, 2024
-
August 27, 2024
RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN’S AUTUMN SLEEP HEALTH WEEKS
-
August 22, 2024
-
August 14, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
Latest Financial Reports
Consolidated Financial Report for First Quarter Financial Results for the Fiscal Year Ending March 31, 2025
Financial Information
Latest Presentations
- First Quarter Financial Results for FY2024 (August 2, 2024)
- First Quarter Financial Results for FY2024 (Webcast) (August 2, 2024)
- Presentation at The Alzheimer’s Association International Conference (AAIC) 2024: Perspectives Session:
Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer’s Disease? - Presentation at The Alzheimer’s Association International Conference (AAIC) 2024: Featured Research Session:
Beyond Amyloid Removal with Lecanemab Treatment: Update on Long-Term Imaging and Fluid Biomarkers
-
Management Policy
-
Value Creation Report (Former Integrated Report) / Human Capital Report
-
Financial Data
Electronic Public Notice
No corporate bonds have been issued at present.